AJUNTAMENT D'ALCOI
Website
Generalitat Valenciana
Website
Ayuntamiento de Valencia
Website
Cicloplast
Website
Ayuntamiento de Onil
Website
Anarpla
Website
Ayuntamiento de Mislata
Website
nlWA, North London Waste Authority
Website
Ayuntamiento de Salinas
Website
Zicla
Website
Fondazione Ecosistemi
Website
PEFC
Website
ALQUIENVAS
Website
DIPUTACI� DE VAL�NCIA
Website
AYUNTAMIENTO DE REQUENA
Website
UNIVERSIDAD DE ZARAGOZA
Website
OBSERVATORIO CONTRATACIÓN PÚBLICA
Website
AYUNTAMIENTO DE PAIPORTA
Website
AYUNTAMIENTO DE CUENCA
Website
BERL� S.A.
Website
CM PLASTIK
Website
TRANSFORMADORES INDUSTRIALES ECOL�GICOS
INDUSTRIAS AGAPITO
Website
RUBI KANGURO
Website
If you want to support our LIFE project as a STAKEHOLDER, please contact with us: life-future-project@aimplas.es
In this section, you can access to the latest technical information related to the FUTURE project topic.
STAT3 decoy oligonucleotide-carrying microbubbles with pulsed ultrasound for enhanced therapeutic effect in head and neck tumors
Signal transducer and activator of transcription-3 (STAT3) is an oncogenic transcription factor implicated in carcinogenesis, tumor progression, and drug resistance in head and neck squamous cell carcinoma (HNSCC). A decoy oligonucleotide targeting STAT3 offers a promising anti-tumor strategy, but achieving targeted tumor delivery of the decoy with systemic administration poses a significant challenge. We previously showed the potential for STAT3 decoy-loaded microbubbles, in conjunction with ultrasound targeted microbubble cavitation (UTMC), to decrease tumor growth in murine squamous cell carcinoma. As a next step towards clinical translation, we sought to determine the anti-tumor efficacy of our STAT3 decoy delivery platform against human HNSCC and the effect of higher STAT3 decoy microbubble loading on tumor cell inhibition. STAT3 decoy was loaded on cationic lipid microbubbles (STAT3-MB) or loaded on liposome-conjugated lipid microbubbles to form STAT3-loaded liposome-microbubble complexes (STAT3-LPX). UTMC treatment efficacy with these two formulations was evaluated in vitro using viability and apoptosis assays in CAL33 (human HNSCC) cells. Anti-cancer efficacy in vivo was performed in a CAL33 tumor murine xenograft model. UTMC with STAT3-MB caused significantly lower CAL33 cell viability compared to UTMC with STAT3-LPX (56.8?8.4% vs 84.5?8.8%, respectively, p
» Author: Thiruganesh Ramasamy, Xucai Chen, Bin Qin, Daniel E. Johnson, Jennifer R. Grandis, Flordeliza S. Villanueva
» Reference: https://doi.org/10.1371/journal.pone.0242264
» Publication Date: 18/11/2020
C/ Gustave Eiffel, 4
(València Parc Tecnològic) - 46980
PATERNA (Valencia) - SPAIN
(+34) 96 136 60 40
Project Management department - Sustainability and Industrial Recovery
life-future-project@aimplas.es